Exicure, Inc. filed a Form 8-K with the SEC on November 20, 2026, disclosing that it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. on November 19, 2026.

Key Highlights

  • New agreement: Exicure entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd.
  • Agreement date: The agreement was executed on November 19, 2026.
  • Strategic focus: The expansion is into medical device technologies designed to assist patients with Parkinson's disease, according to the filing.
  • Disclosure channel: The announcement was made via a press release issued on November 20, 2026, furnished as Exhibit 99.1.
  • Signing authority: The filing was signed by Jung Soo Kim, Chief Executive Officer of Exicure, Inc.

Exicure's Strategic Move Into Parkinson's Medical Device Technologies

Exicure, Inc. (NASDAQ:XCUR) disclosed through an Item 7.01 Regulation FD filing that it entered into a Strategic Business Expansion and Investment Agreement on November 19, 2026, with two counterparties: NeuroQ Biologics Inc. and Laonz Co., Ltd. According to the filing, the agreement is connected to the company's "strategic expansion into medical device technologies designed to assist patients with Parkinson's disease."

The company issued a press release on November 20, 2026, announcing the agreement, a copy of which was furnished as Exhibit 99.1 to the Current Report. The filing does not include financial terms, valuation details, or other specifics of the agreement beyond identifying the parties and the stated strategic focus.

The filing notes that information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing." Exicure is incorporated in Delaware and lists its principal offices at 103 Foulk Road #202, Wilmington, Delaware 19803.

What Was Disclosed

Exicure, Inc. disclosed the execution of a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd., dated November 19, 2026, related to medical device technologies for Parkinson's disease patients. No financial terms were included in the filing.